

# Tore Skotland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5518033/publications.pdf>

Version: 2024-02-01

68  
papers

5,736  
citations

159585

30  
h-index

102487

66  
g-index

70  
all docs

70  
docs citations

70  
times ranked

9637  
citing authors

#	ARTICLE	IF	CITATIONS
1	Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. <i>Nano Today</i> , 2011, 6, 176-185.	11.9	1,063
2	Lipids in exosomes: Current knowledge and the way forward. <i>Progress in Lipid Research</i> , 2017, 66, 30-41.	11.6	751
3	Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013, 1831, 1302-1309.	2.4	546
4	Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. <i>Journal of Lipid Research</i> , 2019, 60, 9-18.	4.2	418
5	An emerging focus on lipids in extracellular vesicles. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 308-321.	13.7	289
6	Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers. <i>European Journal of Cancer</i> , 2017, 70, 122-132.	2.8	254
7	Clathrin-independent endocytosis: mechanisms and function. <i>Current Opinion in Cell Biology</i> , 2011, 23, 413-420.	5.4	200
8	Identification of prostate cancer biomarkers in urinary exosomes. <i>Oncotarget</i> , 2015, 6, 30357-30376.	1.8	179
9	Shiga toxins. <i>Toxicon</i> , 2012, 60, 1085-1107.	1.6	169
10	Clathrin-independent endocytosis: an increasing degree of complexity. <i>Histochemistry and Cell Biology</i> , 2018, 150, 107-118.	1.7	148
11	Protein toxins from plants and bacteria: Probes for intracellular transport and tools in medicine. <i>FEBS Letters</i> , 2010, 584, 2626-2634.	2.8	108
12	The Ether Lipid Precursor Hexadecylglycerol Stimulates the Release and Changes the Composition of Exosomes Derived from PC-3 Cells. <i>Journal of Biological Chemistry</i> , 2015, 290, 4225-4237.	3.4	102
13	Shiga toxin and its use in targeted cancer therapy and imaging. <i>Microbial Biotechnology</i> , 2011, 4, 32-46.	4.2	95
14	Retrograde transport of protein toxins through the Golgi apparatus. <i>Histochemistry and Cell Biology</i> , 2013, 140, 317-326.	1.7	82
15	Interdigitation of long-chain sphingomyelin induces coupling of membrane leaflets in a cholesterol dependent manner. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2016, 1858, 281-288.	2.6	76
16	Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 98, 80-85.	4.0	73
17	In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan®, $\text{Fe}_3\text{O}_4$ ), a contrast agent for magnetic resonance imaging. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 28, 323-329.	2.8	69
18	Lipid requirements for entry of protein toxins into cells. <i>Progress in Lipid Research</i> , 2014, 54, 1-13.	11.6	69

#	ARTICLE	IF	CITATIONS
19	The role of PS 18:0/18:1 in membrane function. <i>Nature Communications</i> , 2019, 10, 2752.	12.8	65
20	Glycosphingolipid Requirements for Endosomeâ€”Golgi Transport of Shiga Toxin. <i>Traffic</i> , 2009, 10, 868-882.	2.7	60
21	New metal-based nanoparticles for intravenous use: requirements for clinical success with focus on medical imaging. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2010, 6, 730-737.	3.3	60
22	Molecular imaging: challenges of bringing imaging of intracellular targets into common clinical use. <i>Contrast Media and Molecular Imaging</i> , 2012, 7, 1-6.	0.8	52
23	Cell-Penetrating Peptides: Possibilities and Challenges for Drug Delivery in Vitro and in Vivo. <i>Molecules</i> , 2015, 20, 13313-13323.	3.8	51
24	Protection against Shiga Toxins. <i>Toxins</i> , 2017, 9, 44.	3.4	51
25	The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 581-592.	2.5	47
26	Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer. <i>Biomacromolecules</i> , 2020, 21, 1489-1498.	5.4	45
27	Cell density-induced changes in lipid composition and intracellular trafficking. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 1097-1116.	5.4	42
28	Cytotoxicity of Poly(Alkyl Cyanoacrylate) Nanoparticles. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2454.	4.1	38
29	Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. <i>Journal of Controlled Release</i> , 2019, 293, 183-192.	9.9	38
30	The role of lipid species in membranes and cancer-related changes. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 343-360.	5.9	34
31	Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114326.	13.7	33
32	Determining the Turnover of Glycosphingolipid Species by Stable-Isotope Tracer Lipidomics. <i>Journal of Molecular Biology</i> , 2016, 428, 4856-4866.	4.2	32
33	Development of nanoparticles for clinical use. <i>Nanomedicine</i> , 2014, 9, 1295-1299.	3.3	30
34	The Ether Lipid Precursor Hexadecylglycerol Causes Major Changes in the Lipidome of HEp-2 Cells. <i>PLoS ONE</i> , 2013, 8, e75904.	2.5	28
35	Biological response and cytotoxicity induced by lipid nanocapsules. <i>Journal of Nanobiotechnology</i> , 2020, 18, 5.	9.1	26
36	Small variations in nanoparticle structure dictate differential cellular stress responses and mode of cell death. <i>Nanotoxicology</i> , 2019, 13, 761-782.	3.0	23

#	ARTICLE	IF	CITATIONS
37	Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120217.	5.2	23
38	The anti-tumor drug 2-hydroxyoleic acid (Minerval) stimulates signaling and retrograde transport. <i>Oncotarget</i> , 2016, 7, 86871-86888.	1.8	21
39	&lt;p&gt;Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy&lt;/p&gt;. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 6269-6285.	6.7	19
40	Transport of nanoparticles across the endothelial cell layer. <i>Nano Today</i> , 2021, 36, 101029.	11.9	19
41	The Protein Toxins Ricin and Shiga Toxin as Tools to Explore Cellular Mechanisms of Internalization and Intracellular Transport. <i>Toxins</i> , 2021, 13, 377.	3.4	19
42	Data including GROMACS input files for atomistic molecular dynamics simulations of mixed, asymmetric bilayers including molecular topologies, equilibrated structures, and force field for lipids compatible with OPLS-AA parameters. <i>Data in Brief</i> , 2016, 7, 1171-1174.	1.0	15
43	Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. <i>Oncotarget</i> , 2017, 8, 76921-76934.	1.8	15
44	NC100668, A NEW TRACER FOR IMAGING OF VENOUS THROMBOEMBOLISM: DISPOSITION AND METABOLISM IN RATS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 111-120.	3.3	13
45	Novel actions of 2-deoxy-D-glucose: protection against Shiga toxins and changes in cellular lipids. <i>Biochemical Journal</i> , 2015, 470, 23-37.	3.7	13
46	The ether lipid precursor hexadecylglycerol protects against Shiga toxins. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 4285-4300.	5.4	12
47	Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding. <i>Scientific Reports</i> , 2016, 6, 30336.	3.3	12
48	Exogenous lysophospholipids with large head groups perturb clathrin-mediated endocytosis. <i>Traffic</i> , 2017, 18, 176-191.	2.7	12
49	Injection of nanoparticles into cloven-hoof animals: Asking for trouble. <i>Theranostics</i> , 2017, 7, 4877-4878.	10.0	12
50	Doping and drug testing. <i>EMBO Reports</i> , 2017, 18, 351-354.	4.5	8
51	Physicochemical Characterization, Toxicity and <i>In Vivo</i> Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin. <i>Journal of Biomedical Nanotechnology</i> , 2020, 16, 419-431.	1.1	8
52	Changes of protein solutions during storage: a study of albumin pharmaceutical preparations. <i>Biotechnology and Applied Biochemistry</i> , 2010, 55, 121-130.	3.1	7
53	Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft. <i>Nanomaterials</i> , 2021, 11, 1140.	4.1	7
54	Need for more focus on lipid species in studies of biological and model membranes. <i>Progress in Lipid Research</i> , 2022, 86, 101160.	11.6	7

#	ARTICLE	IF	CITATIONS
55	NC100668, a New Tracer Tested for Imaging of Venous Thromboembolism: Pharmacokinetics and Metabolism in Humans. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1979-1984.	3.3	6
56	Whole-body section fluorescence imaging – a novel method for tissue distribution studies of fluorescent substances. <i>Contrast Media and Molecular Imaging</i> , 2009, 4, 73-80.	0.8	6
57	Cabazitaxel-loaded poly(alkyl cyanoacrylate) nanoparticles: Toxicity and changes in the proteome of breast, colon and prostate cancer cells. <i>Nanotoxicology</i> , 2021, 15, 1-20.	3.0	5
58	Diacylglycerol kinase and phospholipase D inhibitors alter the cellular lipidome and endosomal sorting towards the Golgi apparatus. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 985-1009.	5.4	5
59	Structural Variants of poly(alkylcyanoacrylate) Nanoparticles Differentially Affect LC3 and Autophagic Cargo Degradation. <i>Journal of Biomedical Nanotechnology</i> , 2020, 16, 432-445.	1.1	5
60	Cellular effects of fluorodeoxyglucose: Global changes in the lipidome and alteration in intracellular transport. <i>Oncotarget</i> , 2016, 7, 79885-79900.	1.8	5
61	Are doping tests in sports trustworthy?. <i>EMBO Reports</i> , 2022, 23, e54431.	4.5	5
62	Different roles of the C-terminal end of Stx1A and Stx2A for AB5 complex integrity and retrograde transport of Stx in HeLa cells. <i>Pathogens and Disease</i> , 2015, 73, ftv083.	2.0	3
63	Improving scientific practice in sports-associated drug testing. <i>FEBS Journal</i> , 2019, 286, 2664-2669.	4.7	2
64	Mass spectrometry-based measurements of cyclic adenosine monophosphate in cells, simplified using reversed phase liquid chromatography with a polar characterized stationary phase. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1160, 122384.	2.3	2
65	Shiga toxins. , 2015, , 267-286.		1
66	Cellular uptake of nanoparticles: Involvement of caveolae?. <i>Precision Nanomedicine</i> , 2021, 4, .	0.8	1
67	Modulation of Ricin Intoxication by the Autophagy Inhibitor EACC. <i>Toxins</i> , 2022, 14, 360.	3.4	1
68	How organizers of scientific meetings and journal editors could facilitate transfer of nanomedicine into the clinic. <i>European Journal of Nanomedicine</i> , 2016, 8, .	0.6	0